Doxycycline hyclate for Heart Failure

Phase-Based Progress Estimates
Heart Failure+1 More
All Sexes
What conditions do you have?

Study Summary

This trial is testing whether doxycycline, a drug commonly used to treat skin conditions and gum disease, can also help prevent heart disease in people who have recently had a heart attack.

Eligible Conditions
  • Heart Failure
  • Heart Attack

Treatment Effectiveness

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 3 months post intervention

Month 3
Composite endpoint of mortality and hospital admission due to re-infarction, heart failure, or stroke
3 months post intervention
Infarct size
Left ventricular ejection fraction (LVEF)
Left ventricular end-diastolic volume index (LVEDVi)
Left ventricular end-systolic volume index (LVESVi)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Doxycycline hyclate
1 of 2
Placebo control
1 of 2

Experimental Treatment

Non-Treatment Group

170 Total Participants · 2 Treatment Groups

Primary Treatment: Doxycycline hyclate · Has Placebo Group · Phase 2

Doxycycline hyclate
Experimental Group · 1 Intervention: Placebo · Intervention Types: Drug
Placebo control
PlaceboComparator Group · 1 Intervention: Doxycycline Hyclate · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3 months post intervention

Who is running the clinical trial?

Royal Alexandra HospitalOTHER
13 Previous Clinical Trials
7,209 Total Patients Enrolled
University of AlbertaLead Sponsor
818 Previous Clinical Trials
376,644 Total Patients Enrolled
22 Trials studying Heart Failure
5,081 Patients Enrolled for Heart Failure
Ian Paterson, MDPrincipal InvestigatorDept. of Medicine, University of Alberta
2 Previous Clinical Trials
733 Total Patients Enrolled
1 Trials studying Heart Failure
518 Patients Enrolled for Heart Failure
Richard Coulden, MDPrincipal InvestigatorDept. of Radiology and Diagnostic Imaging, University of Alberta
Kevin Bainey, MDPrincipal InvestigatorDept. of Medicine, University of Alberta
Richard Schulz, PhDStudy ChairDept. of Pediatrics and Pharmacology, University of Alberta
1 Previous Clinical Trials
380 Total Patients Enrolled
Benjamin Tyrrell, MDStudy DirectorDept. of Medicine, University of Alberta
Richard Thompson, MDPrincipal InvestigatorDept. of Biomedical Engineering, University of Alberta
Peter Hwang, MD, PhDStudy DirectorDept. of Medicine, University of Alberta
Raymond Leung, MDPrincipal InvestigatorCK Hui Heart Centre, Royal Alexandra Hospital, Edmonton, Alberta.
Neil Brass, MDPrincipal InvestigatorDept. of Medicine, University of Alberta

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Symptoms must have started within 12 hours of onset.\n
You are 18 years old or older.
You have a diagnosis of acute ST-elevation myocardial infarction (STEMI).